FLIRT

A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphom (follicular lymphoma IV/SC rituximab therapy)

Poster FLIRT	EHA 2022
G. Cartron	Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study.

Poster FLIRT	ASCO 2022
G. Cartron	Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study.

Publications 2021

Lysa 2021_LYSA_Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

Erwan Dumontet, Céline Pangault, David Roulois, Matthis Desoteux, Simon Léonard, Tony Marchand, Maelle Latour, Patricia Legoix, Damarys Loew, Florent Dingli, Joelle Dulong, Erwan Flecher, Cédric Coulouarn, Guillaume Cartron, Thierry Fest, Karin Tarte

Blood . 2021 Jul 8;138(1):57-70. Learn more

Lysa 2021_LYSA_Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape

Frédéric Mourcin, Léa Verdière, David Roulois, Rada Amin, Claire Lamaison, Vonick Sibut, Brice Thamphya, Céline Pangault, Céline Monvoisin, Sarah Huet, Marine Seffals, Sylvain Baulande, Fatima Mechta-Grigoriou, Patricia Legoix, Delphine Rossille, Marion Guirriec, Simon Léonard, Guillaume Cartron, Gilles Salles, Thierry Fest, Karin Tarte

Immunity . 2021 Aug 10;54(8):1901. Learn more